Brigatinib treatment in a patient with advanced NSCLC with XPO1-ALK fusion: a case report
Patients with ALK-rearranged non-small cell lung cancer (NSCLC) who are treated with ALK tyrosine kinase inhibitors (ALK TKIs) have better prognoses. In this case report, we provide evidence of a novel ALK fusion, XPO1-ALK (intergenic), identified by next-generation DNA sequencing in a patient with...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1503262/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832591905573044224 |
|---|---|
| author | Yang Zhang Ke-jie Li Can Wang Chang-lin Zou Meng Su |
| author_facet | Yang Zhang Ke-jie Li Can Wang Chang-lin Zou Meng Su |
| author_sort | Yang Zhang |
| collection | DOAJ |
| description | Patients with ALK-rearranged non-small cell lung cancer (NSCLC) who are treated with ALK tyrosine kinase inhibitors (ALK TKIs) have better prognoses. In this case report, we provide evidence of a novel ALK fusion, XPO1-ALK (intergenic), identified by next-generation DNA sequencing in a patient with advanced lung cancer. After 5 months of brigatinib targeted therapy, the patient clearly experienced tumor disintegration, and this treatment resulted in partial remission. To date, this patient has experienced 5 months of progression-free survival after brigatinib treatment. In addition to reporting the identification of a novel ALK fusion, XPO1-ALK (intergenic), and the sensitivity and safety of brigatinib treatment for lung cancer, this study increased the list of known ALK fusion partners in ALK-positive NSCLC. This case report has a significant clinical reference. |
| format | Article |
| id | doaj-art-52f74c98e59744c99bcaa7e30b89618d |
| institution | Kabale University |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-52f74c98e59744c99bcaa7e30b89618d2025-01-22T05:19:45ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-01-011410.3389/fonc.2024.15032621503262Brigatinib treatment in a patient with advanced NSCLC with XPO1-ALK fusion: a case reportYang ZhangKe-jie LiCan WangChang-lin ZouMeng SuPatients with ALK-rearranged non-small cell lung cancer (NSCLC) who are treated with ALK tyrosine kinase inhibitors (ALK TKIs) have better prognoses. In this case report, we provide evidence of a novel ALK fusion, XPO1-ALK (intergenic), identified by next-generation DNA sequencing in a patient with advanced lung cancer. After 5 months of brigatinib targeted therapy, the patient clearly experienced tumor disintegration, and this treatment resulted in partial remission. To date, this patient has experienced 5 months of progression-free survival after brigatinib treatment. In addition to reporting the identification of a novel ALK fusion, XPO1-ALK (intergenic), and the sensitivity and safety of brigatinib treatment for lung cancer, this study increased the list of known ALK fusion partners in ALK-positive NSCLC. This case report has a significant clinical reference.https://www.frontiersin.org/articles/10.3389/fonc.2024.1503262/fullXPO1-ALKbrigatiniblung adenocarcinomatargeted therapycase report |
| spellingShingle | Yang Zhang Ke-jie Li Can Wang Chang-lin Zou Meng Su Brigatinib treatment in a patient with advanced NSCLC with XPO1-ALK fusion: a case report Frontiers in Oncology XPO1-ALK brigatinib lung adenocarcinoma targeted therapy case report |
| title | Brigatinib treatment in a patient with advanced NSCLC with XPO1-ALK fusion: a case report |
| title_full | Brigatinib treatment in a patient with advanced NSCLC with XPO1-ALK fusion: a case report |
| title_fullStr | Brigatinib treatment in a patient with advanced NSCLC with XPO1-ALK fusion: a case report |
| title_full_unstemmed | Brigatinib treatment in a patient with advanced NSCLC with XPO1-ALK fusion: a case report |
| title_short | Brigatinib treatment in a patient with advanced NSCLC with XPO1-ALK fusion: a case report |
| title_sort | brigatinib treatment in a patient with advanced nsclc with xpo1 alk fusion a case report |
| topic | XPO1-ALK brigatinib lung adenocarcinoma targeted therapy case report |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2024.1503262/full |
| work_keys_str_mv | AT yangzhang brigatinibtreatmentinapatientwithadvancednsclcwithxpo1alkfusionacasereport AT kejieli brigatinibtreatmentinapatientwithadvancednsclcwithxpo1alkfusionacasereport AT canwang brigatinibtreatmentinapatientwithadvancednsclcwithxpo1alkfusionacasereport AT changlinzou brigatinibtreatmentinapatientwithadvancednsclcwithxpo1alkfusionacasereport AT mengsu brigatinibtreatmentinapatientwithadvancednsclcwithxpo1alkfusionacasereport |